Minimal Residual Disease in CLL

Program Objectives

Definition of MRD Negativity

Outcomes in Clinical Trials

Very Deep MRD May Yield CLL “Cure”

MRD Negativity Predicts PFS After Treatment With FC and FCR

MRD Negativity Predicts PFS After Treatment With G-Clb and R-Clb

MRD Negativity Predicts PFS After Treatment With Alemtuzumab

MRD Negativity With Ibrutinib ± Rituximab

MRD Negativity With BR ± Ibrutinib

MRD Negativity With VenR

MRD Negativity With Venetoclax + Obinutuzumab

MRD Negativity With Venetoclax + Ibrutinib

Sequential Benefit in PFS With Log Reduction in MRD

Changes in Assessment of MRD Depth and Effectiveness of Treatment

Comparison of MRD Assessment Techniques

PB vs BM MRD With Chemoimmunotherapy

PB vs BM MRD With Ibrutinib + Obinutuzumab or Venetoclax

PB vs BM MRD With Novel Agents

PB vs BM MRD Assessment in Clinical Practice

Interpreting Historical MRD Assessment Data in the Era of NGS

MRD Negativity as an Endpoint in CLL Trials

Using MRD Status to Guide Treatment Decisions: Potential Implications

Using MRD Status to Guide Treatment Decisions: CIT and Novel Monotherapies

Using MRD Status to Guide Treatment Decisions: Novel Combinations

Anticipating Duration of MRD Negativity

Looking Ahead

Abbreviations

Abbreviations (cont)

Abbreviations (cont)